U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H20N2O3
Molecular Weight 264.3202
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VORINOSTAT

SMILES

ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1

InChI

InChIKey=WAEXFXRVDQXREF-UHFFFAOYSA-N
InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)

HIDE SMILES / InChI

Molecular Formula C14H20N2O3
Molecular Weight 264.3202
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf

Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of histones proteins. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. By inhibiting histone deacetylase, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized. Vorinostat is used for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. Vorinostat is marketed under the name Zolinza by Merck for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after two systemic therapies.

CNS Activity

Curator's Comment: Vorinostat was shown to cross the blood-brain barrier in a mouse model of Huntington's disease. It inhibited the growth of GL26 GBM cells implanted into the brains of mice. Vorinostat treatment induced accumulation of acetylated histones H2B, H3, and H4 in patients with recurrent GBM.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.12 µM [IC50]
0.13 µM [IC50]
0.15 µM [IC50]
0.28 µM [IC50]
1.68 µM [IC50]
57.0 nM [IC50]
1.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Zolinza

Approved Use

Treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.

Launch Date

2006
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.2 μM
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
0.83 uM
400 mg single, oral
dose: 400 mg
route of administration: oral
experiment type: single
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
1.17 uM
400 mg 1 times / day steady, oral
dose: 400 mg
route of administration: oral
experiment type: steady
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.5 μM × h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
4.59 uM*h
400 mg single, oral
dose: 400 mg
route of administration: oral
experiment type: single
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
5.59 uM*h
400 mg 1 times / day steady, oral
dose: 400 mg
route of administration: oral
experiment type: steady
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
1.94 h
400 mg single, oral
dose: 400 mg
route of administration: oral
experiment type: single
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
2.3 h
400 mg 1 times / day steady, oral
dose: 400 mg
route of administration: oral
experiment type: steady
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
29%
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
Doses

Doses

DosePopulationAdverse events​
250 mg 2 times / day multiple, oral
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, 63 years (range: 38 - 74 years)
n = 5
Health Status: unhealthy
Condition: advanced multiple myeloma
Age Group: 63 years (range: 38 - 74 years)
Population Size: 5
Sources:
DLT: Fatigue...
Dose limiting toxicities:
Fatigue (grade 3, 1 patient)
Sources:
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Disc. AE: Thrombocytopenia, Anemia...
Other AEs: Hypotension, Sepsis...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (grade 3-4, 8%)
Anemia (grade 3-4, 17%)
Deep vein thrombosis (grade 3-4, 25%)
Pyrexia (grade 3-4, 25%)
Pulmonary embolism (grade 3-4, 17%)
Other AEs:
Hypotension (grade 3-4, 17%)
Sepsis (grade 3-4, 8%)
Fatigue (all grades, 27%)
Diarrhea (11%)
Nausea (8%)
Dysgeusia (11%)
Weight loss (3%)
Vomiting (11%)
Anorexia (3%)
Blood creatinine increased (8%)
Dehydration (5%)
Anemia (5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Fatigue grade 3, 1 patient
DLT, Disc. AE
250 mg 2 times / day multiple, oral
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, 63 years (range: 38 - 74 years)
n = 5
Health Status: unhealthy
Condition: advanced multiple myeloma
Age Group: 63 years (range: 38 - 74 years)
Population Size: 5
Sources:
Diarrhea 11%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Dysgeusia 11%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Vomiting 11%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Anorexia 3%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Weight loss 3%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Anemia 5%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Dehydration 5%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Blood creatinine increased 8%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Nausea 8%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Fatigue all grades, 27%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Hypotension grade 3-4, 17%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Anemia grade 3-4, 17%
Disc. AE
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Pulmonary embolism grade 3-4, 17%
Disc. AE
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Deep vein thrombosis grade 3-4, 25%
Disc. AE
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Pyrexia grade 3-4, 25%
Disc. AE
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Sepsis grade 3-4, 8%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Thrombocytopenia grade 3-4, 8%
Disc. AE
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive
no (co-administration study)
Comment: vorinostat has no inhibitory effect on the tranport of vinblastine
Page: 4, 6, 27
no [IC50 79.8 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no
yes
yes
yes
yes
yes
yes
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth.
2001
Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
2001 Jan-Feb
Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17).
2001 Nov
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.
2001 Sep 11
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling.
2002 Jan 17
One-step SFE-plus-C(18) selective extraction of low-polarity compounds, with lipid removal, from smoked fish and bovine milk.
2002 Nov
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
2003 Apr 15
Phosphorus-based SAHA analogues as histone deacetylase inhibitors.
2003 Aug 21
Gateways to clinical trials.
2003 Dec
Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.
2003 Feb
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
2003 May 15
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
2003 Sep 1
Suberanilohydroxamic Acid. Aton Pharma.
2004 Jul
Role of oxidative enzymatic treatments on enzymatic hydrolysis of softwood.
2004 Jun 5
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
2004 Oct
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.
2004 Sep 15
High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum.
2005
Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
2005 Feb 24
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
2005 Jan
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
2005 Mar
Crystal structure of a bacterial class 2 histone deacetylase homologue.
2005 Nov 18
Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.
2005 Oct
Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.
2005 Sep
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
2006 Jan
5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
2006 Jan
SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.
2006 Jul 1
Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
2006 Mar
Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation.
2006 Mar 3
Patents

Sample Use Guides

400 mg orally once daily with food. If patient is intolerant to therapy, the dose may be reduced to 300 mg orally once daily with food. If necessary, the dose may be further reduced to 300 mg once daily with food for 5 consecutive days each week.
Route of Administration: Oral
Concentrations of vorinostat higher than 0.5 uM significantly inhibited the upregulated gene expression of MMP-1 and MMP-13 induced by IL-1β, whereas 0.1 uM vorinostat showed no obvious effect. Conversely, 0.5 uM vorinostat or higher concentration increased the TIMP-1 expression.
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:47:37 GMT 2023
Edited
by admin
on Sat Dec 16 15:47:37 GMT 2023
Record UNII
58IFB293JI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VORINOSTAT
INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
VORINOSTAT [MI]
Common Name English
NSC-759852
Code English
VORINOSTAT [ORANGE BOOK]
Common Name English
NSC-701852
Code English
N-HYDROXY-N'-PHENYLOCTANEDIAMIDE
Systematic Name English
NSC-748799
Code English
ZOLINZA
Brand Name English
MK0683
Code English
VORINOSTAT [MART.]
Common Name English
MK-0683
Code English
VORINOSTAT [USAN]
Common Name English
OCTANEDIAMIDE, N-HYDROXY-N'-PHENYL-
Systematic Name English
vorinostat [INN]
Common Name English
Vorinostat [WHO-DD]
Common Name English
SUBEROYLANILIDE HYDROXAMIC ACID
Common Name English
VORINOSTAT [JAN]
Common Name English
VORINOSTAT [VANDF]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 177203
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
WHO-VATC QL01XX38
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
EU-Orphan Drug EU/3/11/854
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
LIVERTOX NBK548004
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
NCI_THESAURUS C1946
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
NDF-RT N0000175588
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
FDA ORPHAN DRUG 540116
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
WHO-ATC L01XX38
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
NDF-RT N0000175071
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
FDA ORPHAN DRUG 174203
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
FDA ORPHAN DRUG 169503
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL98
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
SMS_ID
100000088823
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
DRUG CENTRAL
4124
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
CAS
149647-78-9
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
MERCK INDEX
m11502
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY Merck Index
HSDB
7930
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
PUBCHEM
5311
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
RXCUI
194337
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY RxNorm
NSC
759852
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
FDA UNII
58IFB293JI
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
DAILYMED
58IFB293JI
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
MESH
C111237
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
INN
8661
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
NCI_THESAURUS
C1796
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
CHEBI
45716
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
IUPHAR
6852
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
NSC
701852
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
NSC
748799
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
WIKIPEDIA
VORINOSTAT
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
USAN
RR-09
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
EPA CompTox
DTXSID6041133
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
EVMPD
SUB23356
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
DRUG BANK
DB02546
Created by admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
BINDING
IC50
TARGET -> INHIBITOR
BINDING
IC50
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
Enzymatic Inhibition
IC50
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
TARGET -> INHIBITOR
BINDING
IC50
TARGET->WEAK INHIBITOR
BINDING
IC50
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
Enzymatic Inhibition
IC50
TARGET->WEAK INHIBITOR
BINDING
IC50
TARGET -> INHIBITOR
Enzymatic Inhibition
IC50
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
Enzymatic Inhibition
IC50
TARGET -> INHIBITOR
Enzymatic Inhibition
IC50
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
Enzymatic Inhibition
IC50
BINDER->LIGAND
BINDING
TARGET ORGANISM->INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
BINDING
IC50
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
Enzymatic Inhibition
IC50
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
PLASMA
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
URINE
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
blood-to-plasma ratio PHARMACOKINETIC
Tmax PHARMACOKINETIC FED CONDITION

HIGH-FAT MEAL

Volume of Distribution PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

DOSE

Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

FASTED CONDITION